Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Protecting Seniors Access to Medicare Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
Source: Senate LDA
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print; President's American Patients First Blueprint Bipartisan Budget Act of 2018
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Importation - Affordable and Safe Prescription Drug Importation Act (S469)
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print; President's American Patients First Blueprint Bipartisan Budget Act of 2018
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Protecting Seniors Access to Medicare Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Protecting Seniors Access to Medicare Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Cong. Reg. 3 - 2017 Budget President's 2018 Budget Blue Print
Protecting Seniors Access to Medicare Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Protecting Seniors Access to Medicare Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Protecting Seniors Access to Medicare Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Cong. Reg. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Fairness to Pet Owners Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Veterinary Biologics, S. 1200 (Fairness to Pet Owners Act).
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Medicare Access and CHIP Reauthorization Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015.
Medicare Access and CHIP Reauthorization Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015; 21st Century Cures.
Confidential Informant Accountability Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Confidential Informant Accountability Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Combination Drug Development Incentive Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); "Hard to Obtain," Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network
MODDERN Cures Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); "Hard to Obtain," Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network
Lake Tahoe Restoration Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; Patent Trolls (H.R. 3390 - "Innovation Act")
Lake Tahoe Restoration Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; Patent Trolls (H.R. 3390)
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 (The Protecting Consumer Access to Generic Drugs Act of 2009) and S. 369 (The Preserve Access to Affordable Generics Act)
Preserve Access to Affordable Generics Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 (The Protecting Consumer Access to Generic Drugs Act of 2009) and S. 369 (The Preserve Access to Affordable Generics Act)
Commercial Motor Vehicle Advanced Safety Technology Tax Act of 2011
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 and S. 5369
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; Biosimilars and the Part D Coverage Gap Discount; Biosimilars Pass-Through Status in Part B
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Importation - Affordable and Safe Prescription Drug Importation Act (S469)
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print; President's American Patients First Blueprint Bipartisan Budget Act of 2018
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; Biosimilars and the Part D Coverage Gap Discount; Biosimilars Pass-Through Status in Part B
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; Biosimilars and the Part D Coverage Gap Discount; Biosimilars Pass-Through Status in Part B
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; IPAB (Independent Payment Advisory Board); Biosimilars and the Part D Coverage Gap Discount; Biosimilars Pass-Through Status in Part B
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; IPAB (Independent Payment Advisory Board). Biosimilars and the Part D Coverage Gap Discount.
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Veterinary Biologics, S. 1200 (Fairness to Pet Owners Act).
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; IPAB (Independent Payment Advisory Board). Biosimilars and the Part D Coverage Gap Discount.
Prescription Drug User Fee Act VI reauthorization; 21st Century Cures Proposal.
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Cong. Reg. 3 - 2017 Budget President's 2018 Budget Blue Print
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Prescription Drug User Fee Act VI reauthorization; 21st Century Cures Proposal.
Cost Sharing (Preserving Access to Medicines).
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Prescription Drug User Fee Act VI reauthorization; 21st Century Cures Proposal.
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal and Transparency.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Average Sales Price; Reimbursement; 21st Century Cures.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Average Sales Price; Reimbursement; Children Health Insurance Program Act of 2015; 21st Century Cures.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015; 21st Century Cures.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; 21st Century Cures Proposal.
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Food and Drug Administration Proposed Changes Being Effected Labeling Rule; 21st Century Cures Proposal.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference.
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference
Cost Sharing (Preserving Access to Medicines); "Hard to Obtain," Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implmentation]; Food and Drug Administration Proposed CBE Labeling Rule; 21st Century Cures Proposal
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Food and Drug Administration Proposed CBE Labeling Rule
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference
Cost Sharing (Preserving Access to Medicines); CMS Proposed Rule (Protected Classes, etc.); "Hard to Obtain", Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges
Cost Sharing (Preserving Access to Medicines); CMS Proposed Rule (Protected Classes, etc.); "Hard to Obtain"; Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference
Food and Drug Administration Safety & Innovation Act (FDASIA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importationi; Non Interference
Healthcare Exchanges; Protected Classes; CMS Rule
Patent Settlements; Patent Trolls (H.R. 3390 - "Innovation Act")
Healthcare Exchanges; Protected Classes
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference; Supply Chain (H.R. 2775)
Patent Settlements; Patent Trolls (H.R. 3390)
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference; Supply Chain Security
Food and Drug Administration Safety & Innovation Act (FDASIA) - Updates
Shortages; Supply Chain Security; Risk Evaluatioin and Mitigation Strategies (REMS); Compounding
Patent Settlements
Shortages; Supply Chain Security; Risk Evaluation and Mitigation Strategies (REMs); Compounding
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference; Supply Chain Security; Patent Settlements
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Fiscal Cliff; Importation; Non Interference; Supply Chain Security; Patent Settlements
Patent Settlements
Gain Act; Shortages; Supply Chain Security; Risk Evaluation and Mitigation Strategies (REMs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Gain Act; Shortages; Supply Chain Security; Best Pharmaceuticals for Children Act/Pediatric Research Equity Act Reauthorization; Risk Evaluation and Mitigation Strategies (REMS); Generic Drug User Fee Act; Prescription Drug User Fee Act
Drug Shortages; The Preserving Access to Life Saving Medicines Act (S. 296)
Patent Settlements
Patent Settlements
Drug Shortages; The Preserving Access to Life Saving Medicines Act (S. 296)
Health Care Reform; Pricing/Rebates; Importation; Coverage; Independent Patient Advisory Board
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Pard D
Patent Settlements
Gain Act; Shortages; Supply Chain Security; Best Pharmaceuticals for Children Act/Pediatric Research Equity Act Reauthorization; Risk Evaluation and Mitigation Strategies (REMS); Generic Drug User Fee Act; Prescription Drug User Fee Act
Patent Settlements; H.R. 1706 (The Protecting Consumer Access to Generic Drugs Act of 2009) and S. 369 (The Preserve Access to Affordable Generics Act)
Drug Shortages; The Preserving Access to Life Savings Medicines Act (S. 296)
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Drug Shortages; The Preserving Access to Life Savings Medicines Act (S. 296)
Patent Settlements; H.R. 1706 and S. 5369
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Pard D/Debt Ceiling
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; IPAB (Independent Payment Advisory Board). Biosimilars and the Part D Coverage Gap Discount.
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Resolution expressing support for the designation of November 9, 2017 as "National Diabetes Heart Connection Awareness Day."
Prescription Drug User Fee reauthorization.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
Average Sales Price; Reimbursement; 21st Century Cures. CMS Rule Blended J Code for Biosimilars; IPAB (Independent Payment Advisory Board).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Transparency - Fair Drug Pricing Act - Baldwin/McCain.
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Food and Drug Administration Safety & Innovationi Act (FDASIA) - Updates/Implementation
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Food and Drug Administration Safety & Innovation Act (FDASIA) - Updates
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Patent Settlements
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Fiscal Cliff
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Fiscal Cliff
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Drug Shortages; The Preserving Access to Life Savings Medicines Act (s. 296)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE